Targeted therapeutics based on engineered proteins that bind EGFR
US9234028B2 · kind B2 · utility
28Cited by
50References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 1, 2013 |
| Grant date | Jan 12, 2016 |
| Priority date | — |
| Expiry date | Aug 30, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.